Clinical trials: Hyperglycemias
Blood Sugar; High, Blood Sugar; Low
Glycemic Index of Cacao Fruit Pulp in Healthy, Human Subjects
Cacao fruit pulp is a sweet and fruity carbohydrate-rich edible mucilage that is often discarded. The objective of this study is to assess the glycemic response and determine the glycemic index of cacao fruit pulp.
- Trial name
- NCT06294938
- Testing
- Cacao fruit pulp, Dextrose
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Mars Wrigley
Renal Insufficiency, Chronic
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
In this survey study, researchers want to find out more about how physicians are treating patients diagnosed with reduced kidney function (chronic kidney disease, CKD) and high blood sugar level (type 2 diabetes); what physicians…
- Trial name
- AWARE-CKD (NCT04498156)
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) in comparison to exenatide (Byetta®), as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-X (NCT00707031)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Exenatide
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 639 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Impaired Glucose Tolerance
Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance
Purpose of the study: to assess the efficacy of Subetta in the treatment of impaired glucose tolerance to assess the safety of Subetta in the treatment of impaired glucose tolerance.
- Trial name
- NCT03725033
- Testing
- Subetta
- Where
- 44 sites in Russia
- Volunteers
- 538 people
- Sponsor
- Materia Medica Holding
Diabetes Mellitus, Type 2
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
- Trial name
- NCT01280695
- Testing
- MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone
- Where
- 14 sites in United States
- Volunteers
- 129 people
- Sponsor
- Metabolic Solutions Development Company
Hypertension, Impaired Glucose Tolerance
Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance
THE PURPOSE OF THIS STUDY IS TO DETERMINE IF 24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG) IMPROVES INSULIN SENSITIVITY IN SUBJECTS WITH HIGHER THAN NORMAL GLUCOSE LEVELS USING A TEST CALLED THE EUGLYCEMIC CLAMP.
- Trial name
- NCT00241072
- Testing
- valsartan
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novartis
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a…
- Trial name
- Amelia-1 (NCT05455619)
- Testing
- Evexomostat
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- SynDevRx, Inc.
Diabetes Mellitus Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to pioglitazone with or without metformin, over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-P (NCT00763815)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Pioglitazone
- Where
- 150 sites in United States, Austria and 11 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Pre Diabetes, Vascular Stiffness
Dietary Exchanges With Avocado and Mango in Pre-diabetes
The research is designed as a randomized, 2-arm, parallel, controlled, human clinical trial to investigate the effects of avocado and mango consumption for 8 weeks on indices of macro- and micro- vascular function in individuals…
- Conditions
- Pre Diabetes, Vascular Stiffness, Vascular Dilation, Cognitive Change
- Trial name
- AVMa (NCT05353790)
- Testing
- Meals + snacks: control, Meals + snacks: Avocado mango
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Hyperglycemia
OptiScanner Versus Standard Blood Glucose Monitoring
The study is to demonstrate the accuracy of the OptiScanner in measuring blood glucose levels in critically ill patients when compared to a reference YSI 2300 STAT Plus and the Gem 3000, the reference standard for Erasme…
- Trial name
- NCT01720381
- Where
- Belgium
- Volunteers
- 98 people
- Sponsor
- OptiScan Biomedical Corporation
Type 2 Diabetes
Evaluation of Correlations Between Volatile Organic Compounds and Venous Blood Glucose in Subjects With Type 2 Diabetes
The goal of this study is to evaluate correlations between VOCs in the breath and venous blood glucose values in various glycaemic states in people living with Type 2 Diabetes.
- Trial name
- Evo (NCT06621030)
- Testing
- MIB Breath Analyzer
- Volunteers
- 15 people
- Sponsor
- BOYDSENSE
Type 1 Diabetes, Pancreatectomy; Hyperglycemia
Collection of Human Liver Biopsy and Whole Blood Samples From T1DM, TP or PP Patients for Potential Use for Insulin Producing Cells in Future Clinical Studies
In this study, liver samples will be collected, processed and stored in a specialized, clinical grade, cell bank for potential future clinical use.
- Trial name
- NCT04038931
- Testing
- Liver biopsy collection
- Volunteers
- 20 people
- Sponsor
- Orgenesis Ltd.
Hyperglycemia
Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS)
The purpose of this study is to assess safety and device performance of the Medtronic Hospital Glucose Management System (HGMS) for up to 72-hours.
- Trial name
- MAHI (NCT01763567)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Medtronic MiniMed, Inc.
Impaired Glucose Tolerance, Abdominal Obesity
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
The purpose of this study is to evaluate the efficacy of GFT505 80mg compared with placebo in improving Oral Glucose Tolerance Test (OGTT), in patients with impaired glucose tolerance and abdominal obesity, and to assess the…
- Trial name
- NCT01275469
- Testing
- GFT505 80mg
- Where
- 20 sites in France
- Volunteers
- 47 people
- Sponsor
- Genfit
Diabetes Mellitus
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy, safety and tolerability of SYR-472, once daily (QD), in subjects with Type 2 Diabetes Mellitus.
- Trial name
- NCT00653185
- Testing
- SYR-472
- Where
- 87 sites in United States, Chile and 10 more
- Volunteers
- 369 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.
- Trial name
- ENERGY (NCT00928889)
- Testing
- Nateglinide 120 mg, Acarbose 50 mg
- Where
- 6 sites in China
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Hyperglycemia
Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin
The purpose of this study is to compare the use of insulin glargine plus insulin lispro to human regular insulin for treatment of hyperglycemia in the hospital setting in patients without known prior history of diabetes.
- Trial name
- HMH (NCT01136746)
- Testing
- Human regular insulin, Insulin lispro, Insulin glargine
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
PreDiabetes, Aging
Safety and Efficacy of KH-1 for Stimulating Autophagy in Non-diabetic Adults With Elevated Blood Glucose Concentration
Aging significantly impacts overall health and is a risk factor for developing diabetes. An estimated 50% of U.S. adults aged ≥65 years were reported to have prediabetes (defined as having a fasting glucose concentration of…
- Trial name
- NCT06445569
- Testing
- KH-1
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Kalin Health, LLC
Type I Diabetes
Type 1 Diabetic Post Prandial Glycemia Evaluation Using an Algorithm
The aim of this study is to demonstrate the efficacy of an algorithm to anticipate the post prandial glycemic profile in type I diabetic patient.
- Trial name
- EGHYA (NCT05151770)
- Testing
- Measure of glycemia levels and comparison to algorithm predictions
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- M-DT1